Contact Information: SCYNEXIS Media Contact: Rick Rountree Rick Rountree Communications 919-878-1144 SCYNEXIS Investor Relations: Douglas MacDougall MacDougall Biomedical Communications 781-235-3060
SCYNEXIS to Present at the JPMorgan Healthcare Conference on January 8, 2008
| Source: SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - January 7, 2008) - SCYNEXIS, Inc. announced today
its participation in the 26th Annual JPMorgan Healthcare Conference,
January 7-10, 2008 at the Westin St. Francis Hotel in San Francisco. Yves
J. Ribeill, Ph.D., President and CEO, will provide an overview of the
Company and its programs in development at 11:30 a.m. PST on Tuesday,
January 8, 2008 in the Elizabethan C/D room.
About SCYNEXIS
SCYNEXIS is a premier drug discovery and development company headquartered
in Research Triangle Park, North Carolina. SCYNEXIS' mission is to be the
leader in delivering effective and innovative drug pipeline solutions to
its pharmaceutical partners.
SCYNEXIS research teams integrate medicinal chemistry, advanced biological
screening, computational chemistry, bioanalysis and analytical chemistry
and use powerful, proprietary technologies such as the HEOS® Software
Suite, MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to
advance molecules to candidate selection. SCYNEXIS development teams have
been tailored to be especially effective in moving customer projects from
the discovery phase to the clinic. SCYNEXIS process chemistry and
bioanalytical/DMPK departments operate under current GMP/GLP guidelines and
have a strong track record of success. Our website is located at
www.scynexis.com.